Literature DB >> 33863792

HLA Class I Polymorphisms Influencing Both Peptide Binding and KIR Interactions Are Associated with Remission among Children with Atopic Dermatitis: A Longitudinal Study.

David J Margolis1,2, Nandita Mitra3, Brian S Kim4, Jamie L Duke5, Ron A Berna2, Ole J Hoffstad3, Jenna R Wasserman5, Deborah A Ferriola5, Tim L Mosbruger5, Bradley S Wubbenhorst6,7, Kathrine L Nathanson6,7, Dimitri S Monos8,9.   

Abstract

Atopic dermatitis (AD) is a disease of immune dysregulation and skin barrier dysfunction with a relapsing, remitting course and has been associated with several different genetic risk variants. HLA represent a highly variable set of genes that code for cell surface protein molecules involved in the Ag-specific immune response, including the regulation or functioning of T cells, NK cells, and APCs. The purpose of this study was to evaluate associations between HLA class I polymorphisms and the progression of AD over time. We evaluated the associations of AD symptoms and HLA class I polymorphisms based on high-resolution two-field typing in a longitudinal cohort of children with AD (up to 10 y of follow-up). Seven hundred and ninety-two children were evaluated every 6 mo, resulting in 12,752 AD evaluations. Using generalized estimating equations and corrected p values, B*44:02 was found to be associated with AD remission (1.83 [1.35, 2.47]; p = 0.0015). The HLA-B residues at position 116 (d-aspartate) and 80 (T-threonine) were associated with remission (1.42 [1.13, 1.76], p = 0.003; corrected p = 0.028) and (1.45 [1.17, 1.80], p = 0.0008; corrected p = 0.0024), respectively. B80T is a killer-cell Ig-like receptor (KIR) site. Our findings reveal that two axes of immune response (T cell and NK cell) may influence disease progression. Identifying binding pocket changes in addition to other factors (e.g., allergens) that increase the risk or severity of AD can improve our understanding of the immunologic mechanisms associated with AD and may lead to personalized therapies for improving patient care.
Copyright © 2021 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33863792      PMCID: PMC8062288          DOI: 10.4049/jimmunol.2001252

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  50 in total

1.  Thymic stromal lymphopoietin variation, filaggrin loss of function, and the persistence of atopic dermatitis.

Authors:  David J Margolis; Brian Kim; Andrea J Apter; Jayanta Gupta; Ole Hoffstad; Maryte Papadopoulos; Nandita Mitra
Journal:  JAMA Dermatol       Date:  2014-03       Impact factor: 10.282

2.  Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys.

Authors:  M Innes Asher; Stephen Montefort; Bengt Björkstén; Christopher K W Lai; David P Strachan; Stephan K Weiland; Hywel Williams
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

3.  Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis.

Authors:  Madison R Mack; Jonathan R Brestoff; Melissa M Berrien-Elliott; Anna M Trier; Ting-Lin B Yang; Matthew McCullen; Patrick L Collins; Haixia Niu; Nancy D Bodet; Julia A Wagner; Eugene Park; Amy Z Xu; Fang Wang; Rebecca Chibnall; M Laurin Council; Carrie Heffington; Friederike Kreisel; David J Margolis; David Sheinbein; Paola Lovato; Eric Vivier; Marina Cella; Marco Colonna; Wayne M Yokoyama; Eugene M Oltz; Todd A Fehniger; Brian S Kim
Journal:  Sci Transl Med       Date:  2020-02-26       Impact factor: 17.956

Review 4.  The extensive polymorphism of KIR genes.

Authors:  Derek Middleton; Faviel Gonzelez
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

Review 5.  Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations.

Authors:  Kerry S Campbell; Amanda K Purdy
Journal:  Immunology       Date:  2011-01-07       Impact factor: 7.397

6.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.

Authors:  Maureen P Martin; Ying Qi; Xiaojiang Gao; Eriko Yamada; Jeffrey N Martin; Florencia Pereyra; Sara Colombo; Elizabeth E Brown; W Lesley Shupert; John Phair; James J Goedert; Susan Buchbinder; Gregory D Kirk; Amalio Telenti; Mark Connors; Stephen J O'Brien; Bruce D Walker; Peter Parham; Steven G Deeks; Daniel W McVicar; Mary Carrington
Journal:  Nat Genet       Date:  2007-05-13       Impact factor: 38.330

Review 7.  Natural killer cells in atopic and autoimmune diseases of the skin.

Authors:  Dagmar von Bubnoff; Emmanuel Andrès; François Hentges; Thomas Bieber; Tatiana Michel; Jacques Zimmer
Journal:  J Allergy Clin Immunol       Date:  2010-01       Impact factor: 10.793

8.  KIR and their HLA Class I ligands: Two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation.

Authors:  Roberto Littera; Gianbenedetto Piredda; Davide Argiolas; Sara Lai; Elena Congeddu; Paola Ragatzu; Maurizio Melis; Elisabetta Carta; Maria Benigna Michittu; Donatella Valentini; Luisella Cappai; Rita Porcella; Francesco Alba; Maria Serra; Valentina Loi; Roberta Maddi; Sandro Orrù; Giorgio La Nasa; Giovanni Caocci; Roberto Cusano; Marcella Arras; Mauro Frongia; Antonello Pani; Carlo Carcassi
Journal:  PLoS One       Date:  2017-07-07       Impact factor: 3.240

9.  Arginine at positions 13 or 70-71 in pocket 4 of HLA-DRB1 alleles is associated with susceptibility to tuberculoid leprosy.

Authors:  L Zerva; B Cizman; N K Mehra; S K Alahari; R Murali; C M Zmijewski; M Kamoun; D S Monos
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

10.  NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80.

Authors:  M Cella; A Longo; G B Ferrara; J L Strominger; M Colonna
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

View more
  2 in total

1.  Association of KIR Genes and MHC Class I Ligands with Atopic Dermatitis.

Authors:  David J Margolis; Nandita Mitra; Ole J Hoffstad; Brian S Kim; Dimitri S Monos; Elizabeth J Phillips
Journal:  J Immunol       Date:  2021-08-18       Impact factor: 5.426

Review 2.  To Be or Not to Be: The Case of Endoplasmic Reticulum Aminopeptidase 2.

Authors:  Piotr Kuśnierczyk
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.